Vertex, instead, takes a machine-gun approach, designing thousands of compounds to test them against hundreds of potentially disease-causing proteins--all at once, and before scientists even know which protein might be a good target or which compound might actually work.
According to him, Dr Afridi did get suspicious by late April 2011 that there might be a high-value target in the Abbottabad compound, but he still didn't know who it was.